NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
Loading market information…
NSE · LALPATHLAB.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Dr. Lal PathLabs Limited’s quoted price sits in the upper half of its reported 52-week range, 6.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Dr. Lal PathLabs Limited’s forward annual dividend is ₹60.00 per share, paid monthly. The forward yield is 3.15% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Dr. Lal PathLabs Limited’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of ₹10.73. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dr. Lal PathLabs Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to conducting pathological investigations across various specialized fields. These include biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, in addition to other general pathological and radiological studies. Beyond its core testing operations, Dr. Lal PathLabs also offers laboratory staff training, technical support, and full-scale lab management services. As of March 31, 2022, its widespread infrastructure included 277 clinical laboratories, notably a National Reference Lab located in Delhi and a Regional Reference Lab in Kolkata. This is further bolstered by 4,731 patient service centers and 10,599 sample collection points. Founded in 1949, Dr. Lal PathLabs Limited maintains its corporate base in Gurugram, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:00 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | Apr 25, 2025 | ₹6.90+15.38% vs estimate | ₹6.03B-0.2% vs estimate |
|---|
| Q3 2025 | Jan 30, 2025 | ₹5.80-1.19% vs estimate | ₹5.97B-0.01% vs estimate |
|---|
| Q2 2025 | Oct 23, 2024 | ₹15.48+4.1% vs estimate | ₹6.60B-1.32% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
₹9,780.00+₹116.00 (+1.2%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
₹4,613.40+₹33.40 (+0.73%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.13% below the high.
₹2,405.50+₹161.50 (+7.2%)
Laurus Labs Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
₹1,466.50+₹2.30 (+0.16%)
Vijaya Diagnostic Centre Limited’s quoted price sits in the upper half of its reported 52-week range, 7.98% below the high.
₹546.90-₹6.95 (-1.25%)
Metropolis Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
₹455.15-₹60.35 (-11.71%)
Thyrocare Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 31.25% below the high.
₹315.50-₹4.05 (-1.27%)
Suraksha Diagnostic Ltd.’s quoted price sits in the upper half of its reported 52-week range, 12.36% below the high.
